Antibodies against MOG have been associated with a wide variety of clinical phenotypes, including acquired demyelinating syndromes such as optic neuritis, myelitis, acute disseminated encephalomyelitis (ADEM), neuromyelitis optical spectrum disorder (NMOSD), encephalitis, and aseptic meningitis. This evidence concerns the gene MOG and myelitis.